A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of DSP-1053 in Healthy Subjects and in Subjects With Major Depressive Disorder.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of DSP-1053 in Healthy Subjects and in Subjects With Major Depressive Disorder.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2014

At a glance

  • Drugs DSP 1053 (Primary)
  • Indications Depressive disorders
  • Focus Adverse reactions
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 Jun 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Apr 2014 Planned End Date changed from 1 Sep 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top